LianBio
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adam Leo Stone
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 103 Carnegie Center Drive Princeton NJ United States of America 08540
- IPO Date
- Nov 1, 2021
- CIK
- 0001831283
- Website
- lianbio.com
- Similar Companies
- Business
- LianBio (Nasdaq: LIAN), a biopharmaceutical company founded in 2019 and headquartered in Princeton, New Jersey, with operations in Shanghai, China, focuses on developing and commercializing innovative medicines for patients with unmet needs in China and other major Asian markets; its pipeline includes mavacamten, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction licensed from MyoKardia/Bristol Myers Squibb; infigratinib phosphate, an FGFR inhibitor for cholangiocarcinoma and advanced solid tumors licensed from BridgeBio Pharma; TP-03 (lotilaner), a GluCls inhibitor for Demodex blepharitis and meibomian gland disease; NBTXR3 (hafnium oxide nanoparticles) for solid tumors including head and neck cancer previously licensed to Janssen; mometasone furoate for chronic sinusitis; and other candidates targeting cardiovascular, oncology, ophthalmology, respiratory, and inflammatory diseases through strategic partnerships with global biopharma leaders. In February 2024, following a comprehensive strategic review, LianBio's board initiated a wind-down of operations set for substantial completion by year-end 2024, including workforce reductions of over 50%, pursuit of sales for remaining pipeline assets, delisting of American Depositary Shares from Nasdaq effective March 2024, and SEC deregistration; the company declared a special cash dividend of $4.80 per ordinary share (approximately $528 million aggregate) payable in March 2024 to shareholders of record as of February 27, 2024, with full dissolution anticipated by mid-2027 and potential additional distributions from asset sales. Target markets encompass Greater China and Asia, serving patients with high-prevalence conditions like cardiorenal disease and cancer through clinically validated, precision-based therapeutics.
Why Is LianBio (LIAN) Stock Moving Today?
LianBio Announces Voluntarily Delisting from Nasdaq
LianBio Announces Completion of Strategic Review
LianBio Announces Departure of Chief Financial Officer
LianBio Announces Departure of Chief Executive Officer
LianBio's Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra Biosciences
LianBio Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
LianBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
All You Need to Know About LianBio Sponsored ADR (LIAN) Rating Upgrade to Strong Buy
LianBio Announces Topline Results from Phase 3 LIBRA Trial of TP-03 in Chinese Patients with Demodex Blepharitis
Why LianBio Stock Is Shooting Through the Roof This Week
3 Penny Stocks To Buy For Under $5, Are They Worth It?
LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib in Patients with Gastric Cancer at ESMO Congress 2023
Why Is LianBio (LIAN) Stock Up 130% Today?
Why LianBio Stock Is Skyrocketing Today
4 Hot Penny Stocks To Watch With Big News This Week
LianBio Announces Results from Phase 3 EXPLORER-CN Trial of Mavacamten Presented at the European Society of Cardiology Congress and Simultaneous Publication in JAMA Cardiology
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
LianBio Announces First Patient Treated in Phase 1 Trial of SHP2 Inhibitor BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis